For best absorption, leave it on for at least 45 minutes or throughout the day
From there, your care team stays with you through the patient portal for dose adjustments, questions, and ongoing support at no added cost
BPC-157 (Body Protection Compound-157) Investigational synthetic gastric-derived peptide (regenerative / cytoprotective) Pre-filled pen BPC-157 is a synthetic peptide based on a sequence identified in gastric juice
Agonists Exendin-4 (subsequently renamed exenatide, the first FDA approved incretin mimetic), Liraglutide (a longacting DPP-4-resistant GLP-1 receptor agonist), CJC-1131 (a GLP-1 analog engineered for covalent coupling to albumin), Albiglutide (originally referred to as albugon, a recombinant human albumin-GLP-1 protein), ZP10 (an exendin-4 derivative), BIM51077 (subsequently renamed taspoglutide), LY315902 (a DPP-4-resistant GLP-1 analog), LY2428757 (a pegylated GLP-1), LY2199265 (Dulaglutide, an Fc immunoglobulin fusion protein), Semaglutide (a synthetic peptide similar to GLP-1), Lixisenatide (a synthetic peptide similar to exandin-4), and Tirzepatide (LY3298176, a dual agonist of GIP and GLP-1 receptors)
They can help you determine the right schedule based on your diet and wellness goals
11.2.0 software (SAS Institute, Cary, NC, USA)